<DOC>
	<DOCNO>NCT01210989</DOCNO>
	<brief_summary>Nonalcoholic fatty liver disease one common chronic liver diseases worldwide . Nonalcoholic steatohepatitis ( NASH ) active form disease run progressive course may result liver cirrhosis liver cancer . However , yet prove treatment disorder . In cell line animal study , show Phyllanthus urinaria ameliorate NASH reduce oxidative stress lipid accumulation . Phyllanthus ( Hepaguard ) use widely patient chronic liver disease , efficacy NASH confirm human . This study divide two part . In part 1 , 60 patient histology-confirmed NASH randomize receive Hepaguard placebo 24 week test efficacy . Endpoints assess week 24 . The aim part 2 test durability Hepaguard . Forty patient originally Hepaguard randomize continue Hepaguard another 24 week stop treatment . The endpoint week 48 analyze .</brief_summary>
	<brief_title>Trial Hepaguard® Adults With Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description>Nonalcoholic fatty liver disease ( NAFLD ) common chronic liver disease affluent country . Patients nonalcoholic steatohepatitis ( NASH ) , severe form NAFLD characterize ballooning , lobular inflammation liver fibrosis , increase mortality rate risk cardiovascular disease . Besides , patient progress cirrhosis may even develop hepatocellular carcinoma . In long-term study , 13 % NAFLD patient die hepatic complication . ( 1 ) Owing westernization lifestyle , NAFLD also increase dramatically Asia . In population screening study Shanghai use ultrasonography , 15 % adult Chinese find suffer NAFLD . ( 2 ) Among Chinese patient NAFLD , significant necroinflammation liver fibrosis uncommon . ( 3-5 ) These patient also often progression liver fibrosis time . ( 6 ) Since NASH closely related type 2 diabetes obesity , logical approach would improve metabolic parameter . ( 7 , 8 ) Observational study suggest regular exercise weight reduction benefit NASH patient . At present , registered drug treatment NASH . Although insulin sensitizer pioglitazone rosiglitazone may improve metabolic profile hepatic necroinflammation , ( 9 , 10 ) effect durable . ( 11 ) Weight gain cardiovascular complication also limit use agent . ( 12 , 13 ) More effective well tolerate treatment urgently need . Phyllanthus urinaria ( Hepaguard® ) commonly use patient various chronic liver disease . ( 14-16 ) Phyllanthus excellent safety profile . In vitro vivo model NAFLD , Phyllanthus reduce hepatic steatosis , necroinflammation fibrosis . ( 16 ) Oxidative stress lipid accumulation ameliorate . Whether beneficial effect apply human unclear . References : 1 . Adams LA , Lymp JF , St Sauver J , Sanderson SO , Lindor KD , Feldstein A , Angulo P. The natural history nonalcoholic fatty liver disease : population-based cohort study . Gastroenterology 2005 ; 129:113-21 . 2 . Fan JG , Zhu J , Li XJ , Chen L , Li L , Dai F , Li F , Chen SY . Prevalence risk factor fatty liver general population Shanghai , China . J Hepatol 2005 ; 43:508-14 . 3 . Wong VW , Chan HL , Hui AY , Chan KF , Liew CT , Chan FK , Sung JJ . Clinical histological feature non-alcoholic fatty liver disease Hong Kong Chinese . Aliment Pharmacol Ther 2004 ; 20:45-9 . 4 . Wong VW , Wong GL , Chim AM , Tse AM , Tsang SW , Hui AY , Choi PC , Chan AW , So WY , Chan FK , Sung JJ , Chan HL . Validation NAFLD fibrosis score Chinese population low prevalence advance fibrosis . Am J Gastroenterol 2008 ; 103:1682-8 . 5 . Wong VW , Wong GL , Tsang SW , Hui AY , Chan AW , Choi PC , Chim AM , Chu S , Chan FK , Sung JJ , Chan HL . Metabolic histological feature non-alcoholic fatty liver disease patient different serum alanine aminotransferase level . Aliment Pharmacol Ther 2009 ; 29:387-96 . 6 . Hui AY , Wong VW , Chan HL , Liew CT , Chan JL , Chan FK , Sung JJ . Histological progression non-alcoholic fatty liver disease Chinese patient . Aliment Pharmacol Ther 2005 ; 21:407-13 . 7 . Wong VW , Hui AY , Tsang SW , Chan JL , Tse AM , Chan KF , So WY , Cheng AY , Ng WF , Wong GL , Sung JJ , Chan HL . Metabolic adipokine profile Chinese patient nonalcoholic fatty liver disease . Clin Gastroenterol Hepatol 2006 ; 4:1154-61 . 8 . Wong VW , Hui AY , Tsang SW , Chan JL , Wong GL , Chan AW , So WY , Cheng AY , Tong PC , Chan FK , Sung JJ , Chan HL . Prevalence undiagnosed diabetes postchallenge hyperglycaemia Chinese patient non-alcoholic fatty liver disease . Aliment Pharmacol Ther 2006 ; 24:1215-22 . 9 . Belfort R , Harrison SA , Brown K , Darland C , Finch J , Hardies J , Balas B , Gastaldelli A , Tio F , Pulcini J , Berria R , Ma JZ , Dwivedi S , Havranek R , Fincke C , DeFronzo R , Bannayan GA , Schenker S , Cusi K. A placebo-controlled trial pioglitazone subject nonalcoholic steatohepatitis . N Engl J Med 2006 ; 355:2297-307 . 10 . Ratziu V , Giral P , Jacqueminet S , Charlotte F , Hartemann-Heurtier A , Serfaty L , Podevin P , Lacorte JM , Bernhardt C , Bruckert E , Grimaldi A , Poynard T. Rosiglitazone nonalcoholic steatohepatitis : one-year result randomize placebo-controlled Fatty Liver Improvement Rosiglitazone Therapy ( FLIRT ) Trial . Gastroenterology 2008 ; 135:100-10 . 11 . Lutchman G , Modi A , Kleiner DE , Promrat K , Heller T , Ghany M , Borg B , Loomba R , Liang TJ , Premkumar A , Hoofnagle JH . The effect discontinue pioglitazone patient nonalcoholic steatohepatitis . Hepatology 2007 ; 46:424-9 . 12 . Balas B , Belfort R , Harrison SA , Darland C , Finch J , Schenker S , Gastaldelli A , Cusi K. Pioglitazone treatment increase whole body fat total body water patient non-alcoholic steatohepatitis . J Hepatol 2007 ; 47:565-70 . 13 . Juurlink DN , Gomes T , Lipscombe LL , Austin PC , Hux JE , Mamdani MM . Adverse cardiovascular event treatment pioglitazone rosiglitazone : population base cohort study . BMJ 2009 ; 339 : b2942 . 14 . Wang M , Cheng H , Li Y , Meng L , Zhao G , Mai K. Herbs genus Phyllanthus treatment chronic hepatitis B : observation three preparation different geographic site . J Lab Clin Med 1995 ; 126:350-2 . 15 . Chan HL , Sung JJ , Fong WF , Chim AM , Yung PP , Hui AY , Fung KP , Leung PC . Double-blinded placebo-controlled study Phyllanthus urinaris treatment chronic hepatitis B. Aliment Pharmacol Ther 2003 ; 18:339-45 . 16 . Shen B , Yu J , Wang S , Chu ES , Wong VW , Zhou X , Lin G , Sung JJ , Chan HL . Phyllanthus urinaria ameliorates severity nutritional steatohepatitis vitro vivo . Hepatology 2008 ; 47:473-83 .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Age 18 year , Histologic NAFLD activity score 3 , Written inform consent Positive hepatitis B surface antigen , antihepatitis C virus antibody , histologic feature alternative liver disease , Alcohol consumption 30g per week men 20g per week woman , Serum alanine aminotransferase 10 time upper limit normal , Liver decompensation , Evidence hepatocellular carcinoma currently past 5 year , Type 1 diabetes insulin treatment , Use investigational drug last 12 week , Terminal illness cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>